Top Markets
Coin of the day
Scilex Holding Company Scilex Holding Company

Scilex Holding Company

SCLX
Kedudukan dalam Saham #25633
Scilex Holding Company is a biopharmaceutical enterprise that specializes in... Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing Phase III trials for lumbosacral radicular pain. Another candidate, SP-103, is progressing through Phase II trials for managing low back pain. Furthermore, SP-104, a novel, low-dose, delayed-release naltrexone hydrochloride formulation, has successfully concluded Phase I clinical testing for the treatment of fibromyalgia. Its corporate offices are situated in Palo Alto, California. Scilex Holding Company operates as a subsidiary of Sorrento Therapeutics, Inc.
Harga Saham
$5.61
Disegerakkan terakhir: 2026-08-20
Modal Pasaran
$47.65M
Perubahan (1 hari)
-0.68%
Perubahan (1 tahun)
-67.26%
Negara
US
Perdagangan Scilex Holding Company (SCLX)

Kategori

Nisbah P/B bagi Scilex Holding Company (SCLX)
Nisbah P/B pada 2026 TTM: 0
Menurut laporan kewangan dan harga saham terkini Scilex Holding Company, nisbah P/B semasa (TTM) ialah 0. Pada akhir 2026, nisbah P/B syarikat ialah 0.
Sejarah nisbah P/B untuk Scilex Holding Company dari 2026 hingga 2026
Nisbah P/B pada akhir setiap tahun
Tahun Nisbah P/B Ubah
Tidak cukup data untuk tarikh yang disediakan.
Nisbah P/B untuk syarikat atau pesaing yang serupa
Syarikat Nisbah P/B Perbezaan Nisbah P/B Negara
31.0864 -
US
7.4766 -
US
-74.4354 -
US
8.4776 -
CH
8.008 -
US